Skip to main content

Table 3 Risk of PCa and other-cause mortality among men on primary ADT compared to observation only

From: Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation

Time period (age)

Relative risk of PCa mortality (95% CI)

Relative risk of mortality due to causes other than PCa (95% CI)

ADT

Observation

ADT

Observation

1985–1994 (70–79y)

1.70 (1.29–2.23)

1.00 (ref)

1.22 (1.00–1.49)

1.00 (ref)

1995–2004

1.55 (1.31–1.84)

1.00 (ref)

1.07 (0.97–1.18)

1.00 (ref)

2005–2014

2.71 (2.08–3.53)

1.00 (ref)

1.03 (0.92–1.16)

1.00 (ref)

1985–1994 (>80y)

1.30 (0.89–1.88)

1.00 (ref)

1.09 (0.85–1.39)

1.00 (ref)

1995–2004

1.49 (1.13–1.97)

1.00 (ref)

1.05 (0.92–1.20)

1.00 (ref)

2005–2014

1.65 (1.19–2.29)

1.00 (ref)

1.06 (0.91–1.23)

1.00 (ref)

  1. p-value for age–period interaction = 0.237; p for age effect = 0.052; p for period effect = 0.005. Analysis is based on propensity matched pairs
  2. PCa prostate cancer, CI confidence interval, ADT androgen deprivation therapy, ref. reference